YAP1 and prostate carcinoma: Combined treatment with two kinds of drugs, namely, the histone deacetylase inhibitory activity of valproic acid (VPA) and simvastatin (SIM), could inhibit the maintenance and progression of CSCs in prostate cancer by inhibiting YAP1 [13].